Age-related macular degeneration (AMD), classified into dry and wet types, poses a significant threat to the vision of the ...

The first-in-human single ascending dose study is designed to evaluate the tolerability and safety of the therapy.

More information: Tiarnan Keenan et al, Oral antioxidant and lutein/zeaxanthin supplements slow geographic atrophy ...

Fixing problems with cholesterol metabolism might help slow or prevent a common cause of age-related vision loss, a new WashU Medicine study in mice has shown.

A new study identifies how the molecule, called ApoM, can clear harmful cholesterol deposits linked to macular degeneration ...

Proposed cuts to the National Institutes of Health and the National Science Foundation “would cause immense and largely ...

"Enrolment concludes in Belite Bio’s trial of Tinlarebant for geographic atrophy" was originally created and published by ...

PulseSight Therapeutics has announced that the first patient has been dosed in its phase 1 clinical trial evaluating PST-611, ...

Geographic Atrophy: Latest Treatments for Personalized Approaches This activity is supported by educational grants from Apellis Pharmaceuticals, Inc.; Astellas; and Topcon Healthcare, Inc.

Washington University researchers found that raising a molecule called ApoM helps eye cells sweep away harmful cholesterol deposits linked to age-related macular degeneration, potentially preventing ...

Findings could help explain the links between macular degeneration and cardiovascular disease, which both worsen with age.

New findings reveal RG6501 cell therapy shows promising long-term visual improvements for geographic atrophy patients ...